Practical Guide to Surgical Data Sets: Surveillance, Epidemiology, and End Results (SEER) Database

Doll, Kemi M.; Rademaker, Alfred; Sosa, Julie Ann

doi:10.1001/jamasurg.2018.0501

Cited by 370 publications

(283 citation statements)

References 6 publications

Supporting

Mentioning

280

Contrasting

Unclassified

Order By: Relevance

“…Patients' data in this study were obtained from Surveillance, Epidemiology, and End Results (SEER) database (SEER 21 Regs Limited‐Field Research Data and Hurricane Katrina Impacted Louisiana Cases, released April 2019, based on the November 2018 submission, vision 8.3.5). The SEER database covers approximately 28% of cancer registries in the United States . The clinical information of cancer patients provided by SEER database greatly facilitates clinical research.…”

Section: Methodsmentioning

confidence: 99%

Prognostic nomograms and Aggtrmmns scoring system for predicting overall survival and cancer‐specific survival of patients with kidney cancer

Zhou¹,

Zhang²,

Ding³

et al. 2020

Cancer Medicine

View full text Add to dashboard Cite

Background: Currently, the prognosis of kidney cancer depends mainly on the pathological grade or tumor stage. Clinicians have few effective tools that can personalize and adequately evaluate the prognosis of kidney cancer patients. Methods: A total of 70 481 kidney cancer patients were selected from the Surveillance, Epidemiology, and End Results database, among which patients diagnosed in 2005-2011 (n = 42 890) were used to establish nomograms for overall survival (OS) and cancer-specific survival (CSS), and those diagnosed in 2012-2015 (n = 24 591) were used for external validation. Univariate and multivariate Cox analyses were used to determine independent prognostic factors. Concordance index (C-index), receiver operating characteristic curve, and calibration curve were used to evaluate the predictive capacity of the nomograms. We further reduced subgroup classification and used propensity score matching to balance clinical informations, and analyzed the effect of other variables on survival. We established a new kidney cancer prognostic score system based on the effect of all available variables on survival. Cox proportional hazard model and Kaplan-Meier curves were used for survival comparison. Results: Age, gender, marital status, surgery, grade, T stage, and M stage were included as independent risk factors in the nomograms. The favorable area under the curve (AUC) value (for OS, AUC = 0.812-0.858; and for CSS, AUC = 0.890-0.921), internal (for OS, C-index = 0.776; and for CSS, C-index = 0.856), and external (for OS, C-index = 0.814-0.841; and for CSS, C-index = 0.894-0.904) validation indi-cated that the proposed nomograms could accurately predict 1-, 3-, and 5-year OS and CSS of kidney cancer patients. The Aggtrmmns prognostic scoring system based on age, gender, race, marital status, grade, TNM stage, and surgery of kidney cancer patients could stage patients more explicitly than the AJCC staging system.

show abstract

Section: Methodsmentioning

confidence: 99%

Prognostic nomograms and Aggtrmmns scoring system for predicting overall survival and cancer‐specific survival of patients with kidney cancer

Zhou¹,

Zhang²,

Ding³

et al. 2020

Cancer Medicine

View full text Add to dashboard Cite

show abstract

“…We used SEER*Stat software version 8.3.5 (https://seer.cancer.gov/seerstat/) to obtain SEER data of about patients with pelvic CS who were diagnosed and treated between 2004 and 2016. This database annually updates the clinical cancer information from 18 regional cancer registries covering ~28% of the US population, including patients’ demographic characteristics, tumor characteristics, therapy details, and follow‐up records …”

Section: Methodsmentioning

confidence: 99%

“…This database annually updates the clinical cancer information from 18 regional cancer registries covering ~28% of the US population, including patients' demographic characteristics, tumor characteristics, therapy details, and follow-up records. 12 As shown in Figure 1, we selected specific cases if sufficient data were available from the database. The inclusion criteria were as follows: (a) diagnosed as 4.2-CS (AYA site recode/ WHO 2008) with the primary site limited to diagnosis code C41.4 (pelvic bones; International Classification of Diseases, 10th edition); (b) positive histological confirmation of CS; (c) completed follow-up; (d) available information about months of survival and causes of death.…”

Section: Data Source and Selectionmentioning

confidence: 99%

Prognostic nomograms to predict overall survival and cancer‐specific survival in patients with pelvic chondrosarcoma

et al. 2019

View full text Add to dashboard Cite

Background The pelvis is the most common site of chondrosarcoma (CS), and the prognosis for patients with pelvic CS is worse than that for patients with CS in the extremities. However, clinicians have had few tools for estimating the likelihood of survival in patients with pelvic CS. Our aim was to develop nomograms to predict survival of patients with pelvic CS. Methods Data from the Surveillance, Epidemiology, and End Results (SEER) database of patients with pelvic CS between 2004 and 2016 were retrieved for retrospective analysis. Univariate and multivariate Cox analyses were used to identify independent prognostic factors. On the basis of the results of the multivariate analyses, nomograms were constructed to predict the likelihood of 3‐ and 5‐year overall survival (OS) and cancer‐specific survival (CSS) of patients with pelvic CS. The concordance index (C‐index) and calibration curves were used to test the models. Results In univariate and multivariate analyses of OS, sex, pathologic grade, tumor size, tumor stage, and surgery were identified as the independent risk factors. In univariate and multivariate analyses of CSS, pathologic grade, tumor size, tumor stage, and surgery were identified as the independent risk factors. These characteristics except surgery were integrated in the nomograms for predicting 3‐ and 5‐year OS and CSS, and the C‐indexes were 0.758 and 0.786, respectively. Conclusion The nomograms precisely and individually predict OS and CSS of patients with pelvic CS and could aid in personalized prognostic evaluation and individualized clinical decision‐making.

show abstract

“…SEER is supported by the National Cancer Institute and collects data on cancer cases from the United States . SEER is a national population‐based registry composed of local registries from 18 states, which report information for all cancer cases within defined regions, with an increased focus on the representation of defined racial and ethnic groups . This study was reviewed and deemed exempt by the Brigham and Women's Hospital Institutional Review Board.…”

Section: Methodsmentioning

confidence: 99%

New lymph node staging for rectal neuroendocrine tumors

Fields

McCarty

Ma‐Pak

et al. 2018

Journal of Surgical Oncology

View full text Add to dashboard Cite

Background and Objectives: Current guidelines of the American Joint Commission on Cancer (AJCC) for rectal neuroendocrine tumors (NETs) classify tumor nodal status as N0/N1. This staging does not take into consideration the number of positive lymph nodes. The goal of this study is to determine how the number of positive lymph nodes affects the prognosis for patients with rectal NETs. Methods: The National Cancer Database was used to identify patients with rectal NETs who underwent rectal resection. Nearest-neighborhood grouping was used to classify patients by survival to create a new nodal staging system. Results: There were 687 patients with rectal NETs. There were distinct 5-year survival estimates for patients with N0 [81.8% (95%CI:77.1%-85.6%)], N1 (1-4 positive lymph nodes) [57.8% (95% confidence interval (CI: 51.2%-63.9%)] and N2 (≥5 positive lymph nodes) [32.6% (95%CI:25.1%-40.3%)] patients, P < 0.0001. Distinct 5-year survival estimates using the new nodal staging system was apparent for patients in the external validation set. After adjusting for predictors of survival in multivariable analysis, the new nodal stage remained an independent predictor of overall survival. Conclusions: The number of positive locoregional lymph nodes is an independent prognostic factor in rectal NETs. The next AJCC edition should consider classifying patients with rectal NETs as N0, N1, and N2 to provide better estimates of survival for patients. K E Y W O R D S AJCC staging, carcinoid tumor, lymph nodes, rectal cancer, rectal neuroendocrine tumor 1 | INTRODUCTION Gastroenteropancreatic neuroendocrine tumors (NETs) have varied behaviors and prognoses depending on their location in the gastrointestinal tract. The rectum is one of the most common sites of gastrointestinal NETs with an age-adjusted incidence of approximately 1 per 100,000. 1,2 Furthermore, the incidence of rectal NETs has increased tenfold over the past 30 years. 3 Tumor size, depth of invasion, and lymph node status are important prognostic factors. 4-6 The five-year survival after diagnosis with rectal NETs is typically higher than other NET sites and exceeds 88%. 4 This is likely due to tumors being localized at the time of diagnosis. 2 Once rectal NETs metastasize, however, five-year survivaldrops to 36%-73% in the presence of regional lymph node metastasis and to 15%-30% for distant metastasis. 2,7,8 In 2010, the American Joint Commission on Cancer (AJCC) published its first TNM staging classification for rectal NETs; locoregional lymph node metastases were characterized as present or absent (N1/N0) and continue to be characterized in this system in the 2017 AJCC 8th edition. 9 This staging system matches the classification developed by the European Neuroendocrine Tumor Society (ENETS) and North American Neuroendocrine J Surg Oncol. 2019;119:156-162. wileyonlinelibrary.com/journal/jso 156 |

show abstract

Practical Guide to Surgical Data Sets: Surveillance, Epidemiology, and End Results (SEER) Database

Cited by 370 publications

References 6 publications

Prognostic nomograms and Aggtrmmns scoring system for predicting overall survival and cancer‐specific survival of patients with kidney cancer

Prognostic nomograms and Aggtrmmns scoring system for predicting overall survival and cancer‐specific survival of patients with kidney cancer

Prognostic nomograms to predict overall survival and cancer‐specific survival in patients with pelvic chondrosarcoma

New lymph node staging for rectal neuroendocrine tumors

Contact Info

Product

Resources

About